ArticleJournal of nanobiotechnology2025
Novel multifunctional targeted nanozyme as an ultrasound contrast agent for real-time monitoring and treatment of congenital hydronephrosis renal fibrosis.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanozymes in the Treatment of Pediatric Inflammatory Diseases: Opportunities and Challenges.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCongenital Hydronephrosis (CH) is a common pediatric disorder that often leads to renal fibrosis (RF), significantly impairing kidney function. Oxidative stress (OS) plays a central role in the pathogenesis of RF. Current treatments lack effective monitoring and targeted therapies for CH, thus highlighting the need for innovative diagnostic and therapeutic approaches. This study explores a novel multifunctional nanozyme, pH-responsive PEG-SH and imidazole-modified gold nanoparticles (PMIZ-AuNPs), for both real-time ultrasound monitoring and treatment of CH-induced RF.
resultsWe designed a pH-responsive nanozyme, consisting of PEG-SH and PMIZ-AuNPs. This nanozyme exhibits enhanced ultrasound imaging properties and dual catalytic activities, including superoxide dismutase (SOD) and catalase (CAT), under acidic conditions. In a unilateral ureteral obstruction (UUO) mouse model, PMIZ-AuNPs accumulated at injury sites, enhancing ultrasound signal intensity and improving RF. Protein sequencing and bioinformatics analysis identified C9 as a critical gene involved in RF. Further experiments showed that PMIZ-AuNPs reduced C9 expression by inhibiting OS and modulated the TGF-β signaling pathway, leading to significant attenuation of RF in both in vitro and in vivo models.
conclusionPMIZ-AuNPs demonstrate significant potential as a multifunctional tool for the diagnosis and treatment of CH-induced RF. By targeting oxidative stress and modulating C9 expression, PMIZ-AuNPs improve renal function and offer a promising strategy for the clinical management of CH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.